PBAC's latest decision on Ivermectin: Recommended with restriction (2014). Considered for Treatment of scabies when prior topical treatment has failed or is contra-indicated, and treatment of crusted scabies in conjunction with topical therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Adults and children (excluding those aged less than 5 years and/or weighing less than 15kg) with typical scabies after failure of both permethrin and benzyl benzoate, or with crusted scabies in conjunction with topical therapy.
Therapy area
Dermatology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Clinical cure
Pivotal trial size
55 patients
Key trials
Macotela–Ruiz, Strong and Johnstone (Cochrane Review)
Comparator
placebo for crusted scabies; benzyl benzoate for typical scabies after failure of topical treatment
Economic model
Cost-consequence
ICER note
Cost-consequence analysis presented; cost per cure calculated but not expressed as a traditional ICER ($/QALY or $/LY). Economic analysis focused on cost per cure rather than cost-effectiveness ratio.